See more : TZP Strategies Acquisition Corp. (TZPSW) Income Statement Analysis – Financial Results
Complete financial analysis of MDxHealth SA (MDXH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MDxHealth SA, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Bellicum Pharmaceuticals, Inc. (BLCM) Income Statement Analysis – Financial Results
- Glenmark Pharmaceuticals Limited (GLENMARK.NS) Income Statement Analysis – Financial Results
- BLB Limited (BLBLIMITED.NS) Income Statement Analysis – Financial Results
- Beyond Commerce, Inc. (BYOC) Income Statement Analysis – Financial Results
- Euro Sun Mining Inc. (CPNFF) Income Statement Analysis – Financial Results
MDxHealth SA (MDXH)
About MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.19M | 37.05M | 22.24M | 18.37M | 11.79M | 28.34M | 40.51M | 29.87M | 17.47M | 11.48M | 7.55M | 4.92M | 3.48M | 3.37M | 3.65M | 4.21M | 3.85M | 3.66M | 3.65M | 525.97K |
| Cost of Revenue | 26.26M | 17.84M | 11.83M | 10.52M | 11.93M | 11.65M | 10.20M | 10.10M | 6.91M | 6.45M | 5.79M | 1.19M | 344.76K | 492.09K | 256.46K | 338.28K | 656.10K | 72.59K | 135.02K | 12.20K |
| Gross Profit | 43.93M | 19.22M | 10.41M | 7.85M | -144.00K | 16.69M | 30.31M | 19.76M | 10.56M | 5.03M | 1.76M | 3.72M | 3.14M | 2.88M | 3.39M | 3.87M | 3.19M | 3.58M | 3.51M | 513.77K |
| Gross Profit Ratio | 62.58% | 51.87% | 46.82% | 42.72% | -1.22% | 58.88% | 74.81% | 66.17% | 60.47% | 43.78% | 23.31% | 75.72% | 90.10% | 85.41% | 92.97% | 91.96% | 82.96% | 98.02% | 96.30% | 97.68% |
| Research & Development | 6.38M | 7.56M | 6.67M | 4.54M | 9.00M | 1.81M | 1.83M | -332.00K | 2.10M | 742.00K | 1.58M | 3.29M | 6.23M | 9.06M | 18.75M | 15.31M | 15.60M | 11.41M | 6.85M | 6.23M |
| General & Administrative | 23.01M | 23.54M | 5.07M | 4.15M | 5.68M | 6.19M | 5.35M | 3.95M | 2.97M | 2.50M | 1.86M | 1.80M | 6.20M | 4.98M | 5.75M | 4.33M | 3.59M | 2.50M | 1.80M | 1.40M |
| Selling & Marketing | 36.92M | 26.58M | 2.59M | 2.31M | 4.43M | 9.07M | 8.15M | 7.61M | 6.02M | 4.91M | 2.50M | 2.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 59.93M | 50.12M | 7.65M | 6.46M | 10.10M | 15.26M | 13.51M | 11.56M | 8.99M | 7.40M | 4.36M | 4.75M | 6.20M | 4.98M | 5.75M | 4.33M | 3.59M | 2.50M | 1.80M | 1.40M |
| Other Expenses | 4.96M | -559.00K | 22.93M | 23.97M | 23.92M | 31.71M | 27.25M | 21.39M | 13.85M | 12.22M | 11.90M | 7.46M | -93.32K | -33.25K | 0.00 | 1.39K | -77.27K | -242.84K | -72.25K | -67.78K |
| Operating Expenses | 71.26M | 57.12M | 37.25M | 34.97M | 43.03M | 48.78M | 42.58M | 32.61M | 24.94M | 20.37M | 17.83M | 15.50M | 12.34M | 14.01M | 24.50M | 19.64M | 19.25M | 14.18M | 8.72M | 7.70M |
| Cost & Expenses | 97.52M | 74.95M | 49.08M | 45.50M | 54.95M | 60.44M | 52.78M | 42.71M | 31.85M | 26.82M | 23.63M | 16.70M | 12.68M | 14.50M | 24.76M | 19.98M | 19.91M | 14.25M | 8.86M | 7.71M |
| Interest Income | 1.09M | 125.00K | 11.00K | 4.00K | 10.00K | 21.00K | 0.00 | 6.00K | 13.00K | 14.00K | 16.00K | 87.29K | 277.36K | 295.25K | 644.74K | 1.59M | 1.53M | 868.43K | 138.57K | 146.40K |
| Interest Expense | 5.58M | 6.14M | 1.88M | 1.35M | 318.00K | 82.00K | 0.00 | 0.00 | 99.00K | 23.00K | 20.00K | 357.08K | 82.95K | 113.05K | 28.65K | 12.53K | 1.61M | 1.11M | 210.82K | 214.19K |
| Depreciation & Amortization | 6.86M | 4.91M | 3.04M | 3.33M | 3.42M | 2.94M | 2.21M | 1.72M | 881.00K | 333.00K | 418.00K | 527.68K | 397.90K | 462.83K | 3.29M | 1.40M | 839.81K | 497.56K | 280.70K | 325.34K |
| EBITDA | -30.47M | -36.39M | -23.99M | -23.79M | -39.74M | -29.47M | -10.19M | -11.57M | -13.50M | -14.88M | -15.59M | -9.80M | -9.22M | -10.37M | -16.66M | -13.43M | -12.86M | -8.77M | -4.93M | -6.86M |
| EBITDA Ratio | -43.41% | -89.03% | -107.46% | -130.55% | -338.88% | -104.00% | -24.88% | -37.25% | -77.29% | -130.33% | -203.20% | -228.77% | -244.73% | -307.41% | -470.29% | -303.54% | -395.27% | -276.04% | -135.09% | -1,304.64% |
| Operating Income | -27.33M | -37.90M | -26.84M | -27.12M | -43.17M | -32.10M | -12.27M | -12.85M | -14.38M | -15.34M | -16.07M | -11.78M | -9.20M | -11.13M | -21.11M | -15.77M | -16.00M | -10.35M | -5.14M | -7.12M |
| Operating Income Ratio | -38.93% | -102.28% | -120.69% | -147.63% | -366.30% | -113.27% | -30.30% | -43.01% | -82.34% | -133.65% | -212.75% | -239.50% | -264.12% | -329.89% | -578.14% | -374.54% | -415.41% | -283.00% | -140.80% | -1,353.61% |
| Total Other Income/Expenses | -15.77M | -6.14M | -2.16M | -1.54M | -506.00K | -393.00K | -127.00K | -441.00K | -91.00K | 86.00K | -104.00K | -89.00K | 209.00K | 182.21K | 616.08K | 853.66K | 1.45M | 625.59K | -180.88K | 78.62K |
| Income Before Tax | -43.10M | -44.04M | -29.00M | -28.66M | -43.68M | -32.49M | -12.40M | -13.29M | -14.47M | -15.26M | -16.18M | -11.87M | -9.00M | -10.94M | -20.49M | -14.19M | -14.54M | -9.72M | -5.07M | -7.04M |
| Income Before Tax Ratio | -61.40% | -118.86% | -130.41% | -156.01% | -370.60% | -114.66% | -30.61% | -44.49% | -82.86% | -132.90% | -214.12% | -241.36% | -258.54% | -324.49% | -561.26% | -337.04% | -377.70% | -265.90% | -138.98% | -1,338.66% |
| Income Tax Expense | 1.00K | 6.14M | 1.88M | 1.35M | -575.00K | -41.00K | -113.00K | -113.00K | 86.00K | 9.00K | 4.00K | 91.25K | -194.41K | 31.92K | -616.08K | -1.58M | -1.61M | -1.11M | -210.82K | -214.19K |
| Net Income | -43.10M | -50.19M | -30.88M | -30.01M | -43.10M | -32.45M | -12.29M | -13.17M | -14.47M | -15.26M | -16.18M | -11.87M | -9.00M | -10.98M | -20.49M | -14.19M | -14.54M | -9.72M | -5.07M | -7.04M |
| Net Income Ratio | -61.40% | -135.45% | -138.84% | -163.33% | -365.72% | -114.51% | -30.33% | -44.11% | -82.86% | -132.90% | -214.12% | -241.36% | -258.54% | -325.43% | -561.26% | -337.04% | -377.70% | -265.90% | -138.98% | -1,338.66% |
| EPS | -1.66 | -3.16 | -2.53 | -3.61 | -6.89 | -5.63 | -2.46 | -2.86 | -3.51 | -4.39 | -5.38 | -5.38 | -5.23 | -8.32 | -15.55 | -11.98 | -13.46 | -11.33 | -11.10 | -18.76 |
| EPS Diluted | -1.66 | -3.16 | -2.53 | -3.61 | -6.89 | -5.63 | -2.46 | -2.86 | -3.51 | -4.39 | -5.38 | -5.38 | -5.23 | -8.32 | -15.55 | -11.98 | -13.46 | -11.33 | -11.10 | -18.76 |
| Weighted Avg Shares Out | 25.91M | 15.87M | 12.19M | 8.32M | 6.26M | 5.76M | 4.99M | 4.61M | 4.13M | 3.48M | 3.00M | 2.21M | 1.72M | 1.32M | 1.32M | 1.18M | 1.08M | 857.92K | 456.88K | 375.28K |
| Weighted Avg Shares Out (Dil) | 25.91M | 15.87M | 12.19M | 8.32M | 6.26M | 5.76M | 4.99M | 4.61M | 4.13M | 3.48M | 3.00M | 2.21M | 1.72M | 1.32M | 1.32M | 1.18M | 1.08M | 857.92K | 456.88K | 375.28K |
MDxHealth to Participate in Piper Sandler Healthcare Conference
MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate...
MDxHealth SA (MDXH) Q3 2024 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Michael K. McGarrity - Chief Executive Officer and Director Ron Kalfus - Chief Financial Officer Conference Call Participants Vidyun Bais - BTIG Thomas...
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024
Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference call and webcast today at 4:30pm ET IRVINE, CA – November 6,...
MDxHealth Announces Pricing of Offering of Ordinary Shares
MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public...
MDxHealth Announces Launch of Offering of Ordinary Shares
MDxHealth Announces Launch of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM –September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40.0 million...
MDxHealth SA (MDXH) Q2 2024 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH ) Q2 2024 Earnings Conference Call August 21, 2024 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - William Blair Vidyun Bais - BTIG Thomas Vranken -...
MDXH Stock Earnings: MDxHealth Misses EPS, Beats Revenue for Q2 2024
MDxHealth (NASDAQ: MDXH ) just reported results for the second quarter of 2024. MDxHealth reported earnings per share of -42 cents.
MDxHealth Reports Q2 and Half Year 2024 Results
MDxHealth Reports Q2 and Half Year 2024 Results Year-over-year Q2 revenues increase by 32% to $22.2 million Year-over-year H1 revenues increase by 34% to 42.0 million Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA,...
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 Company to Host Conference Call with Live Q&A, August 21, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM –...
MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance
MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today reported preliminary Q2 and half...
Source: https://incomestatements.info
Category: Stock Reports